Tesamorelin 5mg

Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone, engineered with a modification that gives it greater stability than the native GHRH peptide. It carries CAS number 218949-48-5 and a molecular weight of 5195.85. As a well-characterised GHRH analogue, it appears widely in growth-hormone and metabolic research as a reference compound, valued for its structural robustness relative to unmodified releasing hormone in study systems.

Mechanistically, tesamorelin acts as a GHRH-receptor agonist and, in experimental models, is reported to stimulate the pituitary release of growth hormone. Its stabilising modification is described in the research literature as improving resistance to enzymatic degradation compared with native GHRH, which extends its usable profile in study systems. This durability is central to why it serves as a benchmark GHRH analogue in much laboratory work.

Within growth-hormone and metabolic research, tesamorelin is studied for its GHRH-analogue activity and its reported effects on growth-hormone axis behaviour across laboratory and clinical-research literature. Its stability makes it a frequent reference point when comparing releasing-hormone analogues. Laboratories sourcing Tesamorelin UK stock commonly cite this well-established body of work when designing controlled endocrine and metabolic experiments under defined conditions.

Sova Peptides supplies tesamorelin as a lyophilised research material for in-vitro and laboratory study by qualified researchers. Each batch is characterised by reverse-phase HPLC and ESI mass spectrometry, with a batch-linked Certificate of Analysis available to confirm identity and molecular weight. Standard lyophilised-peptide storage and handling apply throughout. This product is supplied strictly for laboratory research use only and is not for human or veterinary use.